echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pioneer Pharmaceuticals completes the first patient administration in the Phase III clinical trial of Prokalutamide in the treatment of hospitalized patients with new crowns in the United States

    Pioneer Pharmaceuticals completes the first patient administration in the Phase III clinical trial of Prokalutamide in the treatment of hospitalized patients with new crowns in the United States

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Suzhou, October 4, 2021/PRNewswire/ - Development Pharmaceutical Co.


    The study (NCT05009732) is a randomized, double-blind, placebo-controlled, global multi-center phase III pivotal clinical trial, which aims to explore the effectiveness and safety of Prokrutamide in the treatment of hospitalized patients with new coronary disease


    Dr.


    About Kaixing Pharmaceutical

    Founded in 2009, Kai Kuang Pharmaceutical focuses on the development and industrialization of potential "best-in-class" and "first-in-class" innovative drugs, and is committed to becoming a leader in the research, development and commercialization of innovative therapies


    Source: Kaifeng Pharmaceutical

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.